4+ day, 5+ hour ago   (872+ words) Sept 9 (Reuters) – Today we feature data from studies being presented at the ongoing European Respiratory Society Congress in Barcelona. A drug being developed by AstraZeneca significantly reduced flare-ups of chronic obstructive pulmonary disease in two late-stage trials, researchers reported on…...

4+ day, 23+ hour ago   (317+ words) Sept 8 (Reuters) – Shares of Dyne Therapeutics and Sarepta slumped on Tuesday after Novartis’ treatment for a muscle-wasting disorder failed in a trial, fueling investor concerns ​about the prospects of similar therapies for the tough-to-treat ‌rare disease. Dyne’s stock led declines…...

5+ day, 3+ hour ago   (192+ words) Sept 8 (Reuters) – AstraZeneca said on Tuesday its cancer drug, Imfinzi, combined with Amgen’s targeted immunotherapy, Imdelltra, significantly ​improved overall survival of extensive-stage ‌small-cell lung cancer patients in a late-stage trial. • The trial tested the combination as a maintenance treatment against…...

5+ day, 10+ hour ago   (176+ words) ZURICH, Sept 8 (Reuters) – Swiss drugmaker Novartis on Tuesday said a late-stage study assessing drug del-desiran’s ​impact on myotonic dystrophy, a form ‌of muscle wasting, had not met its target on a key metric, but reaffirmed its sales guidance through 2030. Novartis…...

6+ day, 4+ hour ago   (191+ words) Sept 7 (Reuters) – Novo Nordisk said on Monday it had halted two additional trials of its ​experimental cardiovascular drug ziltivekimab, further ‌denting the Danish drugmaker’s efforts to diversify beyond its blockbuster obesity and diabetes franchise. In July, Novo said ziltivekimab failed…...

1+ week, 1+ day ago   (464+ words) By Christy Santhosh and Bhanvi Satija Sept 4 (Reuters) – Novartis said on Friday its experimental drug pelacarsen did not cut the risk of major heart attacks and strokes in patients with a genetic risk factor in a late-stage trial, marking a…...

1+ week, 5+ day ago   (311+ words) Sept 1 (Reuters) – Britain’s medicines regulator on Tuesday suspended the use and sale of Amgen’s rare-disease drug Tavneos to new patients, saying the main study supporting its approval was ​unreliable. Sold as Avacopan Vifor in Britain by CSL Vifor, ‌the drug…...

1+ week, 5+ day ago   (461+ words) LONDON, Sept 1 (Reuters) – Swiss drugmaker Novartis said on Tuesday its oral drug remibrutinib outperformed an older treatment in reducing relapses in patients with a form of multiple sclerosis, boosting hopes the medicine could become a blockbuster product. The trial results…...

2+ week, 1+ day ago   (313+ words) By Kamal Choudhury and Mariam Sunny Aug 28 (Reuters) – The U.S. Food and Drug Administration has approved a first-of-its-kind drug from Takeda Pharmaceutical and Protagonist Therapeutics to treat ​a rare blood cancer, the health regulator said on ‌Friday. The approval of…...

2+ week, 3+ day ago   (403+ words) By Raechel Thankam Job Aug 27 (Reuters) – AstraZeneca said on Thursday its asthma drug Tezspire met the main goals of a late-stage trial in patients with a chronic inflammatory disorder of the oesophagus, offering the company a boost ​after a string…...